L Gately1, S A McLachlan2, A Dowling2, J Philip3. 1. Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia. lucyjgately@hotmail.com. 2. Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia. 3. Centre for Palliative Care, St Vincent's Hospital, Melbourne, Australia.
Abstract
BACKGROUND: The median survival of glioblastoma is 12-14 months with less than 10% of patients surviving at least 2 years from diagnosis. Patients diagnosed with glioblastoma face poor prognosis, significant symptom burden, and high care needs. The aim of this study is to undertake a literature review to document the issues encountered by long-term survivors of glioblastoma, a small but important subset of patients. METHODS: MEDLINE, PsychInfo, and EMBASE were searched with core concepts: (1) glioblastoma, (2) survivor, and (3) terms pertaining to survivorship issues. A thematic analysis was undertaken of the three included studies. RESULTS: Long-term survivors of glioblastoma encounter neurologic deficits, impairment in cognition, psychological distress, reduced social function, and future uncertainty. These issues result in the inability to return to work and financial difficulties. Independence in activities of daily living, working memory, and overall quality of life appears to be preserved. CONCLUSIONS: Long-term survivors of glioblastoma continue to have significant symptom burden and care needs. There is currently a paucity of literature surrounding this topic. Further research is required to accurately describe these issues in order for improved supportive care to be implemented in the community and the outpatient setting. IMPLICATIONS FOR CANCER SURVIVORS: Understanding the issues faced by long-term survivor of glioblastoma will provide insight into the care needs of patients as well as support networks required for patients and their carers.
BACKGROUND: The median survival of glioblastoma is 12-14 months with less than 10% of patients surviving at least 2 years from diagnosis. Patients diagnosed with glioblastoma face poor prognosis, significant symptom burden, and high care needs. The aim of this study is to undertake a literature review to document the issues encountered by long-term survivors of glioblastoma, a small but important subset of patients. METHODS: MEDLINE, PsychInfo, and EMBASE were searched with core concepts: (1) glioblastoma, (2) survivor, and (3) terms pertaining to survivorship issues. A thematic analysis was undertaken of the three included studies. RESULTS: Long-term survivors of glioblastoma encounter neurologic deficits, impairment in cognition, psychological distress, reduced social function, and future uncertainty. These issues result in the inability to return to work and financial difficulties. Independence in activities of daily living, working memory, and overall quality of life appears to be preserved. CONCLUSIONS: Long-term survivors of glioblastoma continue to have significant symptom burden and care needs. There is currently a paucity of literature surrounding this topic. Further research is required to accurately describe these issues in order for improved supportive care to be implemented in the community and the outpatient setting. IMPLICATIONS FOR CANCER SURVIVORS: Understanding the issues faced by long-term survivor of glioblastoma will provide insight into the care needs of patients as well as support networks required for patients and their carers.
Authors: Eefje M Sizoo; Linda Dirven; Jaap C Reijneveld; Tjeerd J Postma; Jan J Heimans; Luc Deliens; H Roeline W Pasman; Martin J B Taphoorn Journal: J Neurooncol Date: 2013-10-29 Impact factor: 4.130
Authors: Linda Douw; Martin Klein; Selene Saa Fagel; Josje van den Heuvel; Martin Jb Taphoorn; Neil K Aaronson; Tjeerd J Postma; W Peter Vandertop; Jacob J Mooij; Rudolf H Boerman; Guus N Beute; Jasper D Sluimer; Ben J Slotman; Jaap C Reijneveld; Jan J Heimans Journal: Lancet Neurol Date: 2009-08-07 Impact factor: 44.182
Authors: G M Kiebert; D Curran; N K Aaronson; M Bolla; J Menten; E H Rutten; E Nordman; M E Silvestre; M Pierart; A B Karim Journal: Eur J Cancer Date: 1998-11 Impact factor: 9.162
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert Journal: Brain Date: 2007-09-04 Impact factor: 13.501
Authors: Martin Dobes; Vini G Khurana; Bruce Shadbolt; Sanjiv Jain; Sarah F Smith; Robert Smee; Mark Dexter; Raymond Cook Journal: Surg Neurol Int Date: 2011-12-13
Authors: Thomas F Hack; J Dean Ruether; Marshall Pitz; Brian Thiessen; Lesley F Degner; Dan Chateau Journal: Support Care Cancer Date: 2021-02-17 Impact factor: 3.603
Authors: Louis Garnier; Emilie Charton; Antoine Falcoz; Sophie Paget-Bailly; Dewi Vernerey; Marine Jary; François Ducray; Elsa Curtit Journal: Neurooncol Pract Date: 2020-11-11